For individuals facing permanent vision loss, the dream of regaining the ability to read letters and words can seem impossible, especially when the condition is untreatable. However, a new electronic device offers significant hope. A new electronic eye implant, the PRIMA System, is now demonstrating that it can restore lost visual function, allowing patients to successfully read again.

The Challenge of Irreversible Vision Loss

The device is designed to treat blindness resulting from Geographic Atrophy (GA), which is the advanced and currently unmanaged form of dry Age-related Macular Degeneration (AMD). This disease leads to the gradual death of the light-sensitive cells in the macula, eradicating sharp, centralised vision. With no current medical therapy available, GA is a progressive condition impacting an estimated five million people worldwide.

The Clinical Breakthrough

The promising results stem from a major international clinical trial. The study, which included 38 patients treated across 17 global sites, was recently featured in the New England Journal of Medicine. Key findings revealed highly encouraging functional success:

• 84% of study participants achieved the ability to recognise and read letters, numbers, and full words using the artificial vision provided by the implant.
• Across the group, patients experienced an average improvement equivalent to being able to read five additional lines on a standard ophthalmic vision chart compared to their sight level before the procedure.

These outcomes establish the PRIMA System as the first available device capable of restoring the basic ability to read in eyes that had completely lost central vision.

The Mechanism of Action

This therapy employs sophisticated technology to bypass the non-functional retinal tissue:

1. The implant: The surgical procedure involves placing an extremely thin, SIM card-sized microchip (2mm x 2mm) beneath the centre of the patient’s retina.
2. The external system: The patient wears augmented-reality glasses equipped with a video camera that links to a compact, wearable computer unit.
3. Signal processing: The pocket-sized computer, which uses Artificial Intelligence (AI), acts like a digital translator. It takes the video feed from the glasses, simplifies the complex image (like turning a photograph into a basic sketch), and translates that simplified information into electrical pulses that the microchip can understand. The system also includes a zoom feature, allowing the patient to enlarge text for focusing.
4. Vision interpretation: These electrical signals represent the new form of "sight" information. The pulses are sent through the remaining healthy parts of the patient's natural eye structure—the existing retinal cells and the optic nerve—and continue their journey to the brain. The brain receives these pulses and, after training, learns to interpret them as a visual image, allowing the patient to perceive and read.

To maximise functional recovery, every patient must participate in a comprehensive rehabilitation program spanning several months, learning how to correctly interpret these newly created artificial signals.

Clinical Impact and Accessibility

Following the successful completion of the trial, these findings provide a strong foundation for seeking marketing approval for the device, which is being developed by Science Corporation.

The device offers measurable benefits that extend beyond the physical restoration of vision. Specifically, regaining the ability to read translates directly into enhanced quality of life, aligning with a holistic approach to patient wellbeing. This improvement supports personal independence by enabling patients to manage daily living activities, such as reading prescription labels, managing finances, and accessing information, without relying heavily on caregivers or specialised aids. In a health and social care context, restoring the practical ability to read is crucial as it significantly boosts mental and emotional health, contributing to improved self-esteem, self-determination, and active social participation.

Surgeons involved in the study indicated that the PRIMA chip procedure is routine, safely performed in under two hours. This ease of operation is considered a critical factor for ensuring broad access to this novel treatment for GA in dry AMD patients.

Read more...

Pioneering eye device restores reading vision to blind eyes

Life-changing eye implant helps blind patients read again